Zuckerman Investment Group LLC grew its stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 18.7% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,122,061 shares of the company's stock after acquiring an additional 176,632 shares during the period. Kenvue accounts for 2.3% of Zuckerman Investment Group LLC's investment portfolio, making the stock its 14th biggest holding. Zuckerman Investment Group LLC owned 0.06% of Kenvue worth $23,821,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds also recently bought and sold shares of the company. Handelsbanken Fonder AB lifted its position in shares of Kenvue by 2.9% during the 4th quarter. Handelsbanken Fonder AB now owns 742,184 shares of the company's stock worth $15,846,000 after purchasing an additional 21,222 shares during the last quarter. Alberta Investment Management Corp lifted its holdings in Kenvue by 23.2% during the 4th quarter. Alberta Investment Management Corp now owns 582,895 shares of the company's stock worth $12,445,000 after buying an additional 109,700 shares in the last quarter. Longbow Finance SA lifted its holdings in Kenvue by 5.0% in the fourth quarter. Longbow Finance SA now owns 280,568 shares of the company's stock valued at $5,990,000 after buying an additional 13,287 shares during the period. Steward Partners Investment Advisory LLC increased its holdings in Kenvue by 143.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 47,938 shares of the company's stock valued at $1,023,000 after purchasing an additional 28,216 shares during the last quarter. Finally, CORDA Investment Management LLC. grew its holdings in Kenvue by 1.4% during the fourth quarter. CORDA Investment Management LLC. now owns 1,253,096 shares of the company's stock valued at $26,754,000 after purchasing an additional 17,466 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several equities analysts have recently weighed in on KVUE shares. Barclays decreased their price target on shares of Kenvue from $23.00 to $22.00 and set an "equal weight" rating for the company in a research note on Monday. Citigroup raised their price objective on Kenvue from $21.00 to $22.00 and gave the stock a "neutral" rating in a research note on Monday. UBS Group lowered their price objective on Kenvue from $23.00 to $21.00 and set a "neutral" rating for the company in a research report on Friday, February 7th. Redburn Atlantic initiated coverage on Kenvue in a report on Thursday, April 10th. They issued a "neutral" rating and a $23.50 target price for the company. Finally, Canaccord Genuity Group raised their target price on Kenvue from $24.00 to $29.00 and gave the company a "buy" rating in a research note on Wednesday, March 5th. Eight equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $24.42.
Get Our Latest Stock Report on Kenvue
Kenvue Stock Performance
NYSE:KVUE traded up $0.10 during trading on Tuesday, reaching $22.81. The company's stock had a trading volume of 7,280,465 shares, compared to its average volume of 16,880,112. The firm has a 50 day moving average of $22.69 and a 200-day moving average of $22.40. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The firm has a market cap of $43.60 billion, a price-to-earnings ratio of 43.04, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46.
Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Research analysts expect that Kenvue Inc. will post 1.14 EPS for the current fiscal year.
Kenvue Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were paid a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a yield of 3.59%. Kenvue's dividend payout ratio is 154.72%.
Kenvue Company Profile
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
See Also
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
